Eledon Pharmaceuticals Inc

NASDAQ:ELDN   3:59:53 PM EDT
5.60
-0.13 (-2.27%)
Earnings Announcements

Eledon Pharmaceuticals Reports Fourth Quarter And Full-Year 2020 Operating And Financial Results

Published: 03/30/2021 20:36 GMT
Eledon Pharmaceuticals Inc (ELDN) - Eledon Pharmaceuticals Reports Fourth Quarter and Full-year 2020 Operating and Financial Results.
Q4 Loss per Share $2.13.
Q4 Earnings per Share Estimate $-1.54 -- Refinitiv Ibes Data (analyst estimates).
Had Approximately $114.2 Million in Cash and Cash Equivalents As of December 31, 2020.
Eledon Pharmaceuticals - Believes It Has Sufficient Financial Resources to Fund Up to Four Phase 2 Clinical Trials With At-1501.
Believes It Has Sufficient Financial Resources to Fund Operating Activities Well Into 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.63

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.73

More details on our Analysts Page.